Magnolol may contribute to barrier function improvement on imiquimod‑induced psoriasis‑like dermatitis animal model via the downregulation of interleukin‑23

Guo,Jiun-Wen; Cheng,Yu-Pin; Liu,Chih-Yi; Thong,Haw-Yueh; Lo,Yang; Wu,Chen-Yu; Jee,Shiou-Hwa

doi:10.3892/etm.2021.9876

Magnolol may contribute to barrier function improvement on imiquimod‑induced psoriasis‑like dermatitis animal model via the downregulation of interleukin‑23

Authors:
- Jiun-Wen Guo
- Yu-Pin Cheng
- Chih-Yi Liu
- Haw-Yueh Thong
- Yang Lo
- Chen-Yu Wu
- Shiou-Hwa Jee
View Affiliations

Affiliations: Department of Medical Research, Cathay General Hospital, Taipei 10630, Taiwan, R.O.C., Department of Dermatology, Cathay General Hospital, Taipei 10630, Taiwan, R.O.C., Division of Pathology, Sijhih Cathay General Hospital, New Taipei City 22174, Taiwan, R.O.C., Department of Dermatology, Shin‑Kong Wu Ho‑Su Memorial Hospital, Taipei 11101, Taiwan, R.O.C.
Published online on: March 1, 2021 https://doi.org/10.3892/etm.2021.9876
Article Number: 448
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Psoriasis is a chronic, recurrent, immune‑mediated disease involving the skin and joints. Epidermal hyperproliferation, abnormal keratinocyte differentiation, angiogenesis with blood vessel dilatation, and excess T helper type‑1 (Th‑1) and Th‑17 cell infiltration are the main histopathological features of psoriasis. Magnolol is a polyphenolic compound that exerts its biological properties through a variety of mechanisms such as the NF‑κB/MAPK, Nrf2/HO‑1 and PI3K/Akt pathways. Magnolol has been demonstrated to exert a number of therapeutic effects on dermatological processes, including acting as an anti‑inflammation, antiproliferation and antioxidation agent. However, few studies have been published on the effect of magnolol on psoriasis. Therefore, the present study aimed to elucidate the mechanism of action of magnolol on psoriasis. BALB/c mice were treated topically with imiquimod (IMQ) to induce psoriasis‑like dermatitis, and were randomly assigned to the control, vehicle control, low‑ and high‑dose magnolol, and 0.25% desoximetasone ointment treatment groups in order to investigate skin barrier function, any changes in the levels of cytokines and for the histological assessment. High doses of magnolol were indicated to be able to improve the barrier function following IMQ‑induced barrier disruption. Magnolol activated peroxisome proliferator‑activated receptor‑γ, and also significantly inhibited the protein expression of interleukin (IL)‑23, IL‑1β, IL‑6, tumor necrosis factor‑α and interferon‑γ. However, administering a high dose of magnolol did not lead to any improvement in the clinical and pathological features of the psoriasis severity Taken together, these results demonstrated that downregulation of IL‑23 may contribute to barrier function improvement in a psoriatic skin model.

View Figures

View References

1	Elias PM, Hatano Y and Williams ML: Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 121:1337–1343. 2008.PubMed/NCBI View Article : Google Scholar
2	Azfar RS and Gelfand JM: Psoriasis and metabolic disease: Epidemiology and pathophysiology. Curr Opin Rheumatol. 20:416–422. 2008.PubMed/NCBI View Article : Google Scholar
3	Gudjonsson JE and Elder JT: Psoriasis. In: Fitzpatrick's Dermatology in General Medicine. Goldsmith LA, Kazt SI, Gilchrest BA, Paller AD, Leffell DJ and Wolff K (eds.). McGraw-Hill Companies, Inc., 2012.
4	Boehncke WH and Schon MP: Psoriasis. Lancet. 386:983–994. 2015.PubMed/NCBI View Article : Google Scholar
5	Di Cesare A, Di Meglio P and Nestle FO: The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 129:1339–1350. 2009.PubMed/NCBI View Article : Google Scholar
6	Toussirot E: The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets. 11:159–168. 2012.PubMed/NCBI View Article : Google Scholar
7	Bowcock AM: The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet. 6:93–122. 2005.PubMed/NCBI View Article : Google Scholar
8	Alonso-Castro AJ, Zapata-Bustos R, Dominguez F, Garcia-Carranca A and Salazar-Olivo LA: Magnolia dealbata Zucc and its active principles honokiol and magnolol stimulate glucose uptake in murine and human adipocytes using the insulin-signaling pathway. Phytomedicine. 18:926–933. 2011.PubMed/NCBI View Article : Google Scholar
9	Dominguez F, Chavez M, Garduno-Ramirez ML, Chavez-Avila VM, Mata M and Cruz-Sosa F: Honokiol and magnolol production by in vitro micropropagated plants of Magnolia dealbata, an endangered endemic Mexican species. Nat Prod Commun. 5:235–240. 2010.PubMed/NCBI
10	Kuo DH, Lai YS, Lo CY, Cheng AC, Wu H and Pan MH: Inhibitory effect of magnolol on TPA-induced skin inflammation and tumor promotion in mice. J Agric Food Chem. 58:5777–5783. 2010.PubMed/NCBI View Article : Google Scholar
11	Lee YJ, Lee YM, Lee CK, Jung JK, Han SB and Hong JT: Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther. 130:157–176. 2011.PubMed/NCBI View Article : Google Scholar
12	Lin CF, Hwang TL, Al-Suwayeh SA, Huang YL, Hung YY and Fang JY: Maximizing dermal targeting and minimizing transdermal penetration by magnolol/honokiol methoxylation. Int J Pharm. 445:153–162. 2013.PubMed/NCBI View Article : Google Scholar
13	Shen JL, Man KM, Huang PH, Chen WC, Chen DC, Cheng YW, Liu PL, Chou MC and Chen YH: Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders. Molecules. 15:6452–6465. 2010.PubMed/NCBI View Article : Google Scholar
14	Tanaka K, Hasegawa J, Asamitsu K and Okamoto T: Magnolia ovovata extract and its active component magnolol prevent skin photoaging via inhibition of nuclear factor kappaB. Eur J Pharmacol. 565:212–219. 2007.PubMed/NCBI View Article : Google Scholar
15	Dreier D, Latkolik S, Rycek L, Schnürch M, Dymáková A, Atanasov AG, Ladurner A, Heiss EH, Stuppner H, Schuster D, et al: Linked magnolol dimer as a selective PPARg agonist-Structure-based rational design, synthesis, and bioactivity evaluation. Sci Rep. 7(13002)2017.PubMed/NCBI View Article : Google Scholar
16	Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, et al: Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARg): A review. Biochem Pharmacol. 92:73–89. 2014.PubMed/NCBI View Article : Google Scholar
17	Dreier D, Resetar M, Temml V, Rycek L, Kratena N, Schnürch M, Schuster D, Dirsch VM and Mihovilovic MD: Magnolol dimer-derived fragments as PPARg-selective probes. Org Biomol Chem. 16:7019–7028. 2018.PubMed/NCBI View Article : Google Scholar
18	Mao-Qiang M, Fowler AJ, Schmuth M, Lau P, Chang S, Brown BE, Moser AH, Michalik L, Desvergne B, Wahli W, et al: Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol. 123:305–312. 2004.PubMed/NCBI View Article : Google Scholar
19	Flori E, Mastrofrancesco A, Kovacs D, Bellei B, Briganti S, Maresca V, Cardinali G and Picardo M: The activation of PPARg by 2,4,6-Octatrienoic acid protects human keratinocytes from UVR-induced damages. Sci Rep. 7(9241)2017.PubMed/NCBI View Article : Google Scholar
20	Horvath S, Komlodi R, Perkecz A, Pinter E, Gyulai R and Kemeny A: Methodological refinement of Aldara-induced psoriasiform dermatitis model in mice. Sci Rep. 9(3685)2019.PubMed/NCBI View Article : Google Scholar
21	Chong HT, Yang GN, Sidhu S, Ibbetson J, Kopecki Z and Cowin AJ: Reducing Flightless I expression decreases severity of psoriasis in an imiquimod-induced murine model of psoriasiform dermatitis. Br J Dermatol. 176:705–712. 2017.PubMed/NCBI View Article : Google Scholar
22	van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP and Lubberts E: Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 182:5836–5845. 2009.PubMed/NCBI View Article : Google Scholar
23	Guo JW, Cheng YP, Liu CY, Thong HY, Huang CJ, Lo Y, Wu CY and Jee SH: Salvianolic acid B in microemulsion formulation provided sufficient hydration for dry skin and ameliorated the severity of imiquimod-induced psoriasis-like dermatitis in mice. Pharmaceutics. 12(457)2020.PubMed/NCBI View Article : Google Scholar
24	Lin ZM, Ma M, Li H, Qi Q, Liu YT, Yan YX, Shen YF, Yang XQ, Zhu FH, He SJ, et al: Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-α/IFN-g-induced inflammatory response in keratinocytes and T cell-derived IL-17. Pharmacol Res. 129:443–452. 2018.PubMed/NCBI View Article : Google Scholar
25	Li YL, Du ZY, Li PH, Yan L, Zhou W, Tang YD, Liu GR, Fang YX, Zhang K, Dong CZ and Chen HX: Aromatic-turmerone ameliorates imiquimod-induced psoriasis-like inflammation of BALB/c mice. Int Immunopharmacol. 64:319–325. 2018.PubMed/NCBI View Article : Google Scholar
26	OuYang Q, Pan Y, Luo H, Xuan C and Liu J and Liu J: MAD ointment ameliorates imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice. Int Immunopharmacol. 39:369–376. 2016.PubMed/NCBI View Article : Google Scholar
27	Ramot Y, Mastrofrancesco A, Camera E, Desreumaux P, Paus R and Picardo M: The role of PPARγ-mediated signalling in skin biology and pathology: New targets and opportunities for clinical dermatology. Exp Dermatol. 24:245–251. 2015.PubMed/NCBI View Article : Google Scholar
28	Burgermeister E and Seger R: MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle. 6:1539–1548. 2007.PubMed/NCBI View Article : Google Scholar
29	Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M and Seger R: Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol. 27:803–817. 2007.PubMed/NCBI View Article : Google Scholar
30	Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schrøder HD, Kratchmarova I, Berge RK, Iversen L, Bolund L, et al: Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol. 116:702–712. 2001.PubMed/NCBI View Article : Google Scholar
31	Mastrofrancesco A, Kovacs D, Sarra M, Bastonini E, Cardinali G, Aspite N, Camera E, Chavatte P, Desreumaux P, Monteleone G and Picardo M: Preclinical studies of a specific PPARg modulator in the control of skin inflammation. J Invest Dermatol. 134:1001–1011. 2014.PubMed/NCBI View Article : Google Scholar
32	Demerjian M, Man MQ, Choi EH, Brown BE, Crumrine D, Chang S, Mauro T, Elias PM and Feingold KR: Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol. 15:154–160. 2006.PubMed/NCBI View Article : Google Scholar
33	Poivre M and Duez P: Biological activity and toxicity of the Chinese herb magnolia officinalis rehder & E. Wilson (Houpo) and its constituents. J Zhejiang Univ Sci B. 18:194–214. 2017.PubMed/NCBI View Article : Google Scholar
34	Wen J, Wang X, Pei H, Xie C, Qiu N, Li S, Wang W, Cheng X and Chen L: Anti-psoriatic effects of Honokiol through the inhibition of NF-kappaB and VEGFR-2 in animal model of K14-VEGF transgenic mouse. J Pharmacol Sci. 128:116–124. 2015.PubMed/NCBI View Article : Google Scholar
35	Tsai ZX, Mo SY and Zhu SG: Effect and mechanism of Magnolol on psoriasis mice induced by imiquimod. Chin J Clin Pharmacol. 35:56–59. 2019.(In Chinese).